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Summary
 
The specific intracellular sites at which enzymes act to generate arachidonate-derived
eicosanoid mediators of inflammation are uncertain. We evaluated the formation and function
of cytoplasmic lipid bodies. Lipid body formation in eosinophils was a rapidly (
 
,
 
1 h) inducible
response which was platelet-activating factor (PAF) receptor–mediated, involved signaling
through protein kinase C, and required new protein synthesis. In intact and enucleated eosino-
phils, the PAF-induced increases in lipid body numbers correlated with enhanced production
of both lipoxygenase- and cyclooxygenase-derived eicosanoids. All principal eosinophil eicosanoid-
forming enzymes, 5-lipoxygenase, leukotriene C
 
4
 
 synthase, and cyclooxygenase, were immu-
nolocalized to native as well as newly induced lipid bodies in intact and enucleated eosinophils.
Thus, lipid bodies are structurally distinct, inducible, nonnuclear sites for enhanced synthesis of
paracrine eicosanoid mediators of inflammation.
 
L
 
eukotrienes (LT)
 
1
 
, together with PGs, thromboxanes,
and lipoxins, are the major constituents of a group of
biologically active oxygenated fatty acids known as
eicosanoids. Eicosanoids function as paracrine mediators of
inflammation as well as intracellular signals. Eicosanoids
play major roles in inflammatory responses and have been
implicated in the pathogenesis of many inflammatory dis-
eases, including asthma, psoriasis, rheumatoid arthritis, and
inflammatory bowel disease (1, 2). The synthesis of
eicosanoids is catalyzed by lipoxygenases (LOs) (for LTs,
hydroxyeicosatetraenoic acids, and lipoxins) and PG en-
doperoxide H synthases, also known as cyclooxygenases
(for PGs and thromboxanes). Although the enzymatic
pathways for eicosanoid formation are well understood, the
intracellular sites of action of these enzymes and the cellular
sources of arachidonic acid remain less clear. Recent studies
have focused on the intracellular localization of eicosanoid-
forming enzymes. Cyclooxygenases (COXs) are associated
with cellular membranes, including the endoplasmic retic-
ulum and nuclear membrane (3–5). In contrast, 5-LO has
been localized to the cytoplasm, the perinuclear mem-
brane, and the euchromatin within the nucleus, according
to the cell and activation state used (6–10). While translo-
cation from cytosol to membranes may facilitate interactions
of cytosolic enzymes with membrane-bound arachidonate,
there is increasing evidence that specific compartmentaliza-
tion of eicosanoid formation within cells may relate to the
different autocrine and paracrine functions of eicosanoids
(5, 11). Novel, potential sites for paracrine eicosanoid pro-
duction within inflammatory cells are lipid bodies.
Lipid bodies are lipid-rich cytoplasmic inclusions which
are candidates to play a major role in the formation of
eicosanoid mediators during inflammation. Lipid bodies
characteristically develop in vivo in cells associated with in-
flammation; including leukocytes from joints of patients
with inflammatory arthritis (12–14), the airways of patients
with acute respiratory distress syndrome (15), and casein-
or lipopolysaccharide-elicited guinea pig peritoneal exu-
dates (16). In eosinophils, increased lipid body numbers
have been observed in patients with the hypereosinophilic
syndrome (HES) (17, 18), in biopsies from Crohn’s disease
(19), and the blood of airway antigen-challenged asthmatic
patients (Weller, P.F., unpublished observations). Lipid
bodies are sites of esterified arachidonate localization in
cells including neutrophils and eosinophils (17, 20). In hu-
man eosinophils, by electron microscopic autoradiography
and biochemical analysis of purified lipid bodies, lipid bod-
ies have been shown to incorporate [
 
3
 
H]arachidonic acid
into specific phospholipid classes (17). In addition, up-
 
1
 
Abbreviations used in this paper:
 
 cPLA
 
2
 
, cytosolic phospholipase A
 
2
 
; COX,
cyclooxygenase; HES, hypereosinophilic syndrome; LT, leukotriene; LO,
lipoxygenase; PAF, platelet-activating factor; PKC, protein kinase C;
TBS-BSA, Tris-buffered saline containing 0.1% BSA.
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stream enzymes involved in arachidonic acid release, MAP
kinases, and cytosolic phospholipase A
 
2
 
 (cPLA
 
2
 
) (Yu, W.,
P.T. Bozza, D.M. Tzizik, J.P. Gray, J. Cassara, A.M.
Dvorak, and P.F. Welter, manuscript submitted for publi-
cation) as well as COX (21–23) have been localized to lipid
bodies in several types of leukocytes and other cells. More-
over, we have demonstrated recently that stimuli-elicited
compartmentalization of lipids to form new lipid bodies is
associated with enhanced capacity for eicosanoid genera-
tion, suggesting that the cellular responses leading to lipid
body formation may be important in the formation of
eicosanoid mediators of inflammation (24, 25).
In this study we have evaluated mechanisms involved in
lipid body formation and function in human eosinophils.
We demonstrate that platelet-activating factor (PAF) rap-
idly induces lipid body formation in eosinophils in a recep-
tor-dependent fashion, with subsequent activation of pro-
tein kinase C (PKC) and protein synthesis. By means of
immunocytochemistry, electron microscopic immunogold
localization, and/or subcellular fractionation with Western
blotting, the major eicosanoid-forming enzymes of eosino-
phils, 5-LO, LTC
 
4
 
 synthase, and COX, are present within
native and induced eosinophil lipid bodies. Furthermore,
PAF-elicited lipid body formation is associated with en-
hanced generation of eicosanoids by both intact and enu-
cleated eosinophils, suggesting that lipid bodies may be im-
portant inducible sites for enhanced paracrine eicosanoid
mediator production during inflammation.
 
Materials and Methods
 
PAF (1-
 
O
 
-hexadecyl-2-acetyl-
 
sn
 
-glyceryl-3-phosphorylcholine),
lyso-PAF (1-
 
O
 
-alkyl-
 
sn
 
-glyceryl-3-phosphorylcholine), cheleryth-
rine, pertussis toxin, actinomycin D, cytochalasin B, and A23187
were from Calbiochem Novabiochem Corp. (La Jolla, CA). Cy-
cloheximide was obtained from Sigma Chemical Co. (St. Louis,
MO). 1-acyl-2-(7-octyl BODIPY
 
Ô
 
-1-pentanoyl)-
 
sn
 
-glycerol
was obtained from Molecular Probes (Eugene, OR). WEB 2086
was a gift from Boehringer-Ingelheim (Ingelheim, Germany) and
recombinant 5-LO was a gift of Dr. Jilly Evans, Merck Frosst
(Pointe Claire-Dorval, Quebec, Canada). Antibodies used in-
cluded rabbit anti–5-LO (LO32, courtesy of Dr. Jilly Evans), af-
finity-purified rabbit IgG anti-LTC
 
4
 
 synthase (26), and affinity-
purified rabbit anti-COX (Cayman Chemicals Co., Inc., Ann
Arbor, MI). Specificity of anti–5-LO antiserum was confirmed by
Western blotting with affinity-purified recombinant 5-LO.
 
Human Eosinophil Purification.
 
Human eosinophils were puri-
fied as previously described (27). In brief, fresh human blood was
obtained by venipuncture from healthy adult volunteers and col-
lected into acidified citrate. After addition of 6% dextran 70 (Mc-
Gaw, Irvine, CA), RBCs were allowed to sediment for 1 h at
room temperature. The leukocyte-rich supernatant was overlaid
onto an equal volume of Ficoll-Paque gradient (Pharmacia Bio-
tech, Piscataway, NJ) and centrifuged at 400 
 
g
 
 for 20 min. Granu-
locytes were recovered from the pellet and washed in Ca
 
2
 
1
 
/
Mg
 
2
 
1
 
-free HBSS. Residual RBCs were lysed with hypotonic sa-
line. Eosinophils (
 
.
 
95% pure) were negatively selected with anti-
CD16 immunomagnetic beads (Miltenyi Biotec Inc., Auburn,
CA) to remove neutrophils using the MACS system (Miltenyi
Biotec).
 
Cytoplast Preparation.
 
Cytoplasts were prepared by the method
of Roos et al. (28). Briefly, eosinophils were mixed with 12.5%
(wt/vol) Ficoll 70 containing 20 
 
m
 
M cytochalasin B and incu-
bated for 5 min at 37
 
8
 
C. After incubation, eosinophils were lay-
ered over a discontinuous gradient of 16% and 25% Ficoll 70
containing 20 
 
m
 
M cytochalasin B which had been prewarmed to
37
 
8
 
C. The cells were centrifuged at 82,000 
 
g
 
 for 35 min at 35
 
8
 
C.
Cytoplasts (
 
.
 
90% pure) were recovered from the layer formed at
the 12.5/16% and 16/25% Ficoll interfaces and washed five times
in Ca
 
2
 
1
 
/ Mg
 
2
 
1
 
-free HBSS. Nuclei and granule containing karyo-
plasts were in the pellet.
 
Lipid Body Induction and Treatments.
 
Human eosinophils (10
 
6
 
cells/ml) were incubated with varying concentrations of PAF,
lyso-PAF, or vehicle at 37
 
8
 
C in a 5% CO
 
2
 
, 95% O
 
2
 
 atmosphere;
after the incubation period eosinophils (10
 
5
 
/slide) were cytocen-
trifuged (550 rpm, 5 min) onto glass slides. During inhibitor stud-
ies, eosinophils were pretreated for 1 h with varying concentra-
tions of receptor antagonist, enzyme inhibitors, or vehicle as
indicated. When PKC and protein synthesis inhibitors were used,
the preincubation time was reduced to 30 min to avoid toxic ef-
fect to the cells. The cell viability, determined by trypan blue dye
exclusion at the end of each experiment, was always 
 
.
 
90%. In
selected experiments, apoptosis of eosinophils was monitored by
fluorescence microscopy of cells exposed to propidium iodide (10
 
m
 
g/ml) and annexin V-FITC (1 
 
m
 
g/ml) according to the manu-
facturer’s recommendation (Apoalert apoptosis kit; Clontech,
Palo Alto, CA). Stock solutions for A23187, WEB 2086, and act-
inomycin D were prepared in DMSO and stored at 
 
2
 
20
 
8
 
C. Ali-
quots were diluted in Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS to the indicated
concentration immediately before use. The final DMSO concen-
tration was always 
 
,
 
0.1% and had no effect on lipid body num-
bers. Cycloheximide, chelerythrine, and pertussis toxin were diluted
in Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS. Stock solutions of PAF and lyso-PAF
were prepared in Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS containing 0.1% BSA.
 
Lipid Body Staining and Enumeration.
 
While still moist, eosin-
ophils on cytospun slides were fixed in 3.7% formaldehyde in
Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS, pH 7.4, rinsed in 0.1 M cacodylate
buffer, pH 7.4, stained in 1.5% OsO
 
4
 
 (30 min), rinsed in dH
 
2
 
O,
immersed in 1.0% thiocarbohydrazide (5 min), rinsed in 0.1 M
cacodylate buffer, restained in 1.5% OsO
 
4
 
 (3 min), rinsed in
dH
 
2
 
O, and then dried and mounted. The morphology of fixed
cells was observed, and lipid bodies were enumerated by phase-
contrast microscopy with an 
 
3
 
100 objective lens in 50 consecu-
tively scanned eosinophils.
 
LTC
 
4
 
 and PGE
 
2
 
 Measurement.
 
Human eosinophils or eosino-
phil cytoplasts (10
 
6
 
 cells/ml) were stimulated with PAF (10
 
2
 
8
 
–
10
 
2
 
6
 
 M) or vehicle at 37
 
8
 
C for 1 h for lipid body formation. After
incubations, samples were taken for lipid body enumeration and
eosinophils were washed in Ca
 
2
 
1
 
/Mg
 
2
 
1
 
-free HBSS. Eosinophils
or cytoplasts were resuspended in 1 ml of HBSS containing
Ca
 
2
 
1
 
/Mg
 
2
 
1
 
 and then stimulated with A23187 (0.5 
 
m
 
M) for 15
min. Reactions were stopped on ice, and the samples were cen-
trifuged at 500 
 
g
 
 for 10 min at 4
 
8
 
C. LTC
 
4
 
 and PGE
 
2
 
 in the super-
natants were assayed by ELISA according to the manufacturer’s
instructions (Cayman Chemical Co., Inc.).
 
Immunogold Staining.
 
Electron microscopic preparation of
samples and immunogold staining was performed as described
previously (21, 29). In brief, eosinophils were fixed in suspension
for 1 h at 20
 
8
 
C in a dilute mixture of aldehydes in sodium ca-
codylate buffer, washed overnight at 4
 
8
 
C, centrifuged through
molten agar, postfixed in collidine-buffered osmium tetroxide for
2 h at 20
 
8
 
C, stained en bloc with uranyl acetate, dehydrated in a
graded series of alcohols, infiltrated, and embedded and polymer- 
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ized in a propylene oxide-Epon sequence. Postembedding im-
munogold staining was performed in the following sequence: (
 
a
 
)
freshly cut thin sections on either gold or nickel grids either un-
masked in 2% sodium metaperiodate for 30 min or permeabilized
on 0.1% Triton X-100 in 0.1 M Tris-buffered saline, pH 7.6, for
10 min; (
 
b
 
) three washes of 10 min each in Tris-buffered saline
containing 0.1% BSA (TBS-BSA); (
 
c
 
) block with TBS-BSA con-
taining 5% normal goat serum for 30 or 60 min; (
 
d
 
) incubation at
room temperature for 60 min in a 1:10 dilution of rabbit poly-
clonal antiserum to 5-LO (LO32 from Merck Frosst) in TBS-
BSA containing normal goat serum and 0.1% Tween 20; (
 
e
 
) three
washes of 10 min each in TBS-BSA; (
 
f
 
) incubation for 120 min at
room temperature in a 1:20 dilution of 20-nm gold-labeled goat
anti–rabbit IgG (E.Y. Laboratories, Inc., San Mateo CA); (
 
g
 
) two
washes of 10 min each in TBS-BSA; (
 
h
 
) two washes for 5 min in
distilled water and dried overnight, and (
 
i
 
) staining with dilute
lead citrate for 10 min. Nonimmune rabbit serum or 5-LO solid
phase absorbed anti–5-LO antiserum, prepared as described (19),
at the same dilution as the 5-LO antiserum, were used as controls.
 
Immunocytochemistry.
 
Human eosinophils or eosinophil cyto-
plasts (10
 
6
 
 cells/ml) were stimulated with PAF (10
 
2
 
6
 
 M) at 37
 
8
 
C
for 1 h for lipid body formation. In some experiments, 1 
 
m
 
M of
the fluorescent fatty acid–containing diglyceride, 1-acyl-2-(7-
octyl BODIPY
 
Ô
 
-1-pentanoyl)-
 
sn
 
-glycerol (30), was added to
the incubation in order to fluorescently label lipid bodies. After
the incubation, cells were washed twice in Ca
 
2
 
1
 
/Mg21-free
HBSS, cytospun onto slides, and fixed in 3% formaldehyde at
room temperature for 10 min. Fixed cells were permeabilized
with 0.05% saponin/HBSS solution and then blocked with 10%
normal goat serum. After washing, cytospin preparations were in-
cubated for 1 h at room temperature with the following primary
antibodies which were diluted in 0.05% saponin/HBSS solution:
rabbit polyclonal serum anti–5-LO (1:150 dilution), affinity-puri-
fied rabbit anti-COX IgG (5 mg/ml), or affinity-purified rabbit
anti-LTC4 synthase IgG (5 mg/ml). Nonimmune rabbit serum or
purified rabbit IgG, at the same concentration as the primary anti-
bodies, were used as control. After three washes of 5 min in 0.05%
saponin/HBSS, the preparations were incubated with biotin-con-
jugated goat anti–rabbit IgG (Vector Labs. Inc., Burlingame,
CA). The immunoreactive COX, 5-LO, and LTC4 synthase in
cells were then identified by an ABC Vectastatin glucose-oxidase
kit following the manufacturer’s instructions (Vector Labs. Inc.).
The glucose-oxidase immunostaining was visualized under light
microscopy, and fluorescent lipid bodies were identified under
FITC filter.
Subcellular Fractionation and Western Blotting of 5-LO. Eosinophils
were disrupted and subjected to centrifugation to isolate buoyant
lipid bodies and other subcellular fractions by a modification of a
previous method (17). In brief, eosinophils, purified from an HES
donor, were preincubated with PAF (1 mM) or vehicle for 1 h at
378C before being washed and resuspended in 3 ml of disruption
buffer (25 mM Tris-HCl, 100 mM KCl, 3.5 mM MgCl2, 1 mM
EDTA, 5 mM EGTA, pH 7.4) supplemented with 5 mg/ml cy-
tochalasin B, 10 mg/ml leupeptin, 0.7 mg/ml pepstatin A, 50 mg/
ml  Na-p-tosyl-L-lysine chloro-methyl ketone, and 0.1 mM
PMSF. After 15 min at 48C, cells were disrupted by nitrogen cav-
itation at 800 psi for 10 min. The cavitate was collected dropwise
and mixed with an equal volume of disruption buffer containing
1.08 M sucrose. After centrifugation at 1,500 g for 10 min to pel-
let the nuclei, the supernatants were overlaid with 1.5 ml of 0.27 M
sucrose buffer, 1.5 ml of 0.135 M sucrose buffer, and 1.5 ml of
Top solution (25 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA,
pH 7.4). After centrifugation at 150,500 g for 60 min, four dis-
crete fractions were collected sequentially from top to bottom:
the buoyant lipid body fraction (2.5 ml), the mid-zone between
lipid bodies and cytosol (2.5 ml), the cytosol (5 ml), and the mi-
crosomal pellet. The lipid body and mid-zone fractions contained
2.5% and ,6% of cytosolic LDH activity, respectively, and essen-
tially no microsomal sulfatase C activity, indicating that these
fractions were essentially free of cytosolic and microsomal con-
taminants. The microsomal and nuclear pellets were washed and
resuspended in Top solution by sonication.
Proteins from subcellular fractions were concentrated by pre-
cipitation with 10% TCA overnight at 48C. The precipitates
were then washed twice with cold acetone. Protein concentra-
tions were normalized in each fraction after micro BCA assay
(Pierce Chemical Co., Rockford, IL). Samples (15 mg) of each
fraction were then prepared in reducing and denaturing condi-
tions and separated by electrophoresis in 10% SDS-PAGE gels.
After transfer onto nitrocellulose membranes, nonspecific binding
sites were blocked with 5% nonfat dry milk (Bio-Rad, Hercules,
CA) in Tris-buffered saline–Tween (TBST; 50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, and 0.05% Tween 20) at room tempera-
ture for 1 h. The membranes were then probed with anti-5-LO
serum (1:5,000 dilution) followed by horseradish peroxidase-con-
jugated secondary antibodies (1:5,000 dilution) in TBST with 2%
nonfat dry milk. Detection of antigen–antibody complexes was
performed by Supersignal chemiluminescence (Pierce Chemical
Co.).
Statistical Analysis. Results were expressed as mean 6 SEM
and were analyzed statistically by means of ANOVA followed by
the Newman-Keuls Student test with the level of significance set
at P ,0.05. Correlation coefficients were determined by linear
regression, and correlation analysis was performed by Fisher’s r to
z transformation with the level of significance set at P ,0.05.
Results
Mechanisms of PAF-induced Lipid Body Formation in Eosin-
ophils. Lipid bodies, although small in number, are nor-
mal constituents of leukocytes, including eosinophils. In-
creased lipid body formation occurs in vivo and can be in-
duced in vitro. In eosinophils obtained from normal
donors, within 1 h PAF stimulated a dose-dependent in-
duction of lipid body formation in vitro (Fig. 1 A). In re-
sponse to 1 mM PAF, lipid body numbers persisted at simi-
lar numbers at 1, 4, and 8 h (14.1 6 0.5, 15.9 6 0.7, and
9.5 6 0.5 lipid bodies 6 SEM/eosinophil, respectively)
with no evidence of enhanced cell death or apoptosis (,7%
apoptotic eosinophils at 8 h with and without PAF stimula-
tion). Several findings indicated that the actions of PAF
were receptor mediated. First, lyso-PAF failed to induce
lipid body formation (Fig. 1 A). Second, the PAF-receptor
antagonist WEB 2086 dose-dependently inhibited PAF-
induced lipid body formation (Fig. 1 B). Moreover, earlier
treatment of cells with pertussis toxin (100 ng/ml, 1 h be-
fore PAF) to block PAF-receptor G-protein–mediated sig-
nals completely prevented PAF-induced lipid body forma-
tion in human eosinophils (Fig. 1 B).
Additional intracellular signaling pathways involved in
PAF-induced lipid body formation in human eosinophils
were studied. As shown in Table 1, staurosporine (1–10
mM) and H-7 (25–50 mM) significantly inhibited the in-912 Lipid Bodies: Inducible Sites for Eicosanoid Formation
creases in lipid body numbers induced by PAF in human
eosinophils, thus suggesting a role for PKC in this process.
The involvement of PKC in PAF-induced lipid body for-
mation was confirmed by the ability of two selective PKC
inhibitors, chelerythrine (1–10 mM) and calphostin C (0.5–
1 mM), to almost completely block the induction of lipid
bodies (Table 1). Pretreatment with inhibitors of mRNA
and protein synthesis, actinomycin D (1 mM) and cyclo-
heximide (1 mM), respectively, significantly inhibited PAF-
induced lipid body formation (Table 1), suggesting that
eosinophil lipid body induction depends on gene expres-
sion and de novo protein synthesis.
Immunolocalization of Eicosanoid-forming Enzymes to Eosino-
phil Lipid Bodies. Since human eosinophils form LTC4 as
Figure 1. PAF receptor–medi-
ated induction of lipid body
formation in eosinophils. (A)
Human eosinophils, at a concen-
tration of 106 cells/ml, were
treated with PAF (1028–1026M)
(white squares) or lyso-PAF (1028–
1026 M) (black squares) for 1 h at
378C. (B) Human eosinophils at
a concentration of 106 cells/ml
were pretreated with WEB 2086
(10–100  mM), pertussis toxin
(100 ng/ml), or vehicle for 1 h at
378C. The cells were then
treated with PAF (1 mM) or ve-
hicle for 1 h at 378C. Lipid bod-
ies were enumerated using light
microscopy after osmium stain-
ing. Each point represents the
mean  6 SEM of lipid bodies on 50 consecutive eosinophils from three to five independent assays using different donors. *Statistically significant differ-
ence between PAF and the vehicle. 1Statistically significant differences caused by pretreatment with WEB 2086 or pertussis toxin.
Table 1. Effects of PKC and Protein Synthesis Inhibitors on PAF-induced Lipid Body Formation in Eosinophils
Treatment Dose
Lipid bodies
(mean 6 SEM)/eosinophils Percentage of inhibition
mM
Staurosporine 0 21.8 6 2.1 –
1 14.9 6 1.4* 58
10 12.8 6 0.9* 83
H-7 0 21.8 6 2.1 –
25 14.9 6 1.0* 58
50 11.8 6 1.1 75
Calphostin 0 21.8 6 2.1 –
0.5 13.1 6 1.3* 65
1 11.6 6 0.9* 85
Chelerythrine 0 21.8 6 2.1 –
1 15.7 6 1.6* 51
10 13.0 6 1.3* 73
Actinomycin 0 11.8 6 0.8 –
1 7.9 6 0.3* 60
Cycloheximide 0 11.8 6 0.8 –
1 7.4 6 0.2* 68
Eosinophils (106/ml) were pretreated with PKC or protein synthesis inhibitors for 30 min and then stimulated with PAF (1 mM) or vehicle for 1 h.
Results are mean 6 SEM from three to five experiments with different donors. Percentage of inhibition was calculated using the following formula:
percentage of inhibition 5 100 2 (net No. of PAF-induced lipid bodies in treatment group 3 100) / (net No. PAF-induced lipid bodies with PAF
alone). Basal mean numbers of lipid bodies ranged from 5.3 to 9.8/eosinophil with different donors and have been subtracted to determine the net
induced lipid body numbers. *Statistically significant differences between agonists alone and treated groups.913 Bozza et al.
their principal 5-LO pathway product and form lesser
amounts of COX-derived eicosanoids, we evaluated whether
the key eicosanoid-forming enzymes were localized at
eosinophil lipid bodies, both in naturally formed lipid bod-
ies in eosinophils from HES patients and in lipid bodies in-
duced to form in vitro. The compartmentalization of 5-LO,
LTC4 synthase, and COX to lipid bodies was analyzed by
immunocytochemistry using conditions of cell fixation and
permeabilization that prevent dissolution of lipid bodies.
Human eosinophils were stimulated with PAF (1 mM, for
1 h) to induce lipid body formation, and lipid bodies were
visualized by endogenous labeling with the fluorescent fatty
acid–containing diglyceride, 1-acyl-2-(7-octyl BODIPYÔ-
1-pentanoyl)-sn-glycerol (1 mM) (30). Fluorescent fatty
acid-labeled lipid bodies were visualized as green punctate
intracytoplasmic inclusions (Fig. 2, A and C). Eosinophils
stained with rabbit anti–5-LO antiserum, in addition to
perinuclear membrane and cytosolic staining, showed focal
punctate cytoplasmic staining that coincidently matched
with fluorescent fatty acid–labeled lipid bodies (Fig. 2 B).
There was no immunoreactivity when control, normal rab-
bit serum was used instead of the 5-LO antiserum (Fig. 2 D),
although fluorescent fatty acid-labeled lipid bodies were
strongly visualized (Fig. 2 C). Analogously, eosinophils
Figure 2. Immunolocalization of 5-LO to lipid bodies of human eosinophils. (A and C) Human eosinophils from normal volunteers were incubated
with PAF (1 mM, for 1 h) to induce lipid body formation, and lipid bodies were visualized by endogenous labeling with the fluorescent fatty acid–con-
taining diglyceride, 1-acyl-2-(7-octyl BODIPYÔ-1-pentanoyl)-sn-glycerol (1 mM, for 1 h). Fluorescent fatty acid–labeled lipid bodies were visualized as
green punctate intracytoplasmic inclusions under FITC excitation. (B) With specific anti–5-LO rabbit antiserum and glucose-oxidase immunocytochem-
istry, there was 5-LO staining diffusely in the cytoplasm as well as at punctate lipid bodies (which matched those in A). (D) With control nonimmune
rabbit serum there was no lipid body or cytoplasmic staining.914 Lipid Bodies: Inducible Sites for Eicosanoid Formation
from eosinophilic donors contained lipid bodies exhibiting
specific anti–5-LO staining by glucose oxidase immunocy-
tochemistry (not shown). The immunolocalization of 5-LO
within lipid bodies was confirmed by immunogold electron
microscopy. Freshly isolated, unstimulated eosinophils
from an HES donor, examined by postembedding immu-
nogold with anti–5-LO antiserum, contained lipid bodies
which were extensively labeled with 20 nm gold particles
(Fig. 3, A and C). Substitution of the specific anti–5-LO
antibody with either control 5-LO absorbed anti–5-LO
antisera (Fig. 3 B) or nonimmune serum (Fig. 3 D) yielded
no staining of lipid bodies.
In human eosinophils, LTC4 is the predominant 5-LO
product (31). Recently, human LTC4 synthase, the enzyme
responsible for conjugating glutathione to form LTC4, has
been purified and cloned (26, 32, 33). Using an affinity-
purified rabbit anti-LTC4 synthase IgG (26), this LTC4-
forming enzyme was localized directly to lipid bodies.
Eosinophils induced to form lipid bodies and stained with
anti-LTC4 synthase IgG showed focal cytoplasmic staining
(Fig. 4 B) which matched the fluorescent fatty acid–labeled
lipid bodies (Fig. 4 A). Likewise, eosinophils from an HES
donor showed LTC4 synthase localization at native lipid
bodies (not shown). The enzyme COX was also shown to
colocalize to PAF-induced lipid bodies in eosinophils (Fig.
4, C and D), in agreement with previous immunogold
electron microscopic localization of COX to lipid bodies in
freshly isolated eosinophils (21). Specificity of anti-COX
and anti-LTC4 staining was demonstrated by the absence of
immunoreactivity when nonimmune rabbit IgG was used
instead of the specific primary antibody, under conditions
where fluorescent fatty acid–labeled lipid bodies were
present (Fig. 3, E and F). Thus, 5-LO, LTC4 synthase and
COX were present at lipid bodies within 1 h of their in-
duction as well as in naturally formed lipid bodies in
eosinophils from eosinophilic donors.
Involvement of Lipid Bodies in Enhanced Generation of
Eicosanoids by PAF-stimulated Eosinophils. Because eosino-
phil lipid bodies are sites of intracellular localization of
eicosanoid-forming enzymes (Figs. 2–4) and also stores of
eicosanoid-precursor arachidonic acid (17), we analyzed
whether PAF-induced increases in lipid body numbers in
eosinophils would correlate with increased LTC4 and PGE2
production by human eosinophils. After eosinophils were
incubated with various concentrations of PAF for 1 h, lipid
bodies were enumerated and replicate eosinophils were
stimulated with A23187 (0.5 mM). As shown in Fig. 5,
PAF dose-dependently induced concordant increases in
both lipid body numbers and priming for enhanced LTC4
(Fig. 5 A) and PGE2 (Fig. 5 B) generation. Increases in lipid
body numbers correlated with enhanced production of
each eicosanoid (r 5 0.97, P ,0.03, r 5 0.99, P ,0.001
for LTC4 and PGE2, respectively). If the hypothesis that
lipid bodies have roles in enhanced eicosanoid formation is
correct, then inhibition of lipid body formation should re-
sult in suppressed eicosanoid formation. To test this hy-
pothesis, we used the inhibitors of protein synthesis, acti-
nomycin D and cycloheximide, because these compounds
were effective in blocking lipid body formation induced by
PAF (Table 1). Pretreatment of eosinophils with actinomy-
cin D (1 mM) or cycloheximide (1 mM) inhibited not only
PAF-induced lipid body formation, but also priming for
LTC4 (by 70 and 40% for actinomycin and cycloheximide,
respectively) and PGE2 (by 40 and 54% for actinomycin
and cycloheximide, respectively) release by eosinophils,
under conditions where these inhibitors failed to inhibit
calcium ionophore–induced LTC4 and PGE2 in cells not
prestimulated with PAF (not shown).
Lipid Body Formation, Eicosanoid-forming Enzyme Localiza-
tion, and Priming for Enhanced Generation of Eicosanoids by
PAF-stimulated Enucleated Eosinophils. Recently, several stud-
ies have focused on the role of the perinuclear environment
Figure 3. Immunogold localization of 5-LO in freshly isolated, unstim-
ulated eosinophils from an HES donor shows gold label indicating 5-LO
in lipid bodies (A and C), which was absent from lipid bodies stained with
control solid phase 5-LO–absorbed anti–5-LO antisera (B) or nonim-
mune control serum (D). In A, cytoplasmic tubules and vesicles of
smooth endoplasmic reticulum adjacent to the lipid body also have gold
particles associated with them (arrows) which are absent in the 5-LO ab-
sorption control (arrow, B). The lipid bodies in A and B are not homoge-
neously dense and reveal numerous small, round areas which are electron
lucent and nonmembrane bound. In contrast, lipid bodies in C and D ap-
pear more homogeneous in their content. In C, several gold particles re-
side in the perinuclear cistern (arrow); the nonimmune antibody control
has one gold particle attached to electron-dense chromatin in the nucleus.
A, 329,640; B, 336,480; C, 344,080, D, 345,600.915 Bozza et al.
as a site of eicosanoid-forming enzyme localization and
eicosanoid generation (5, 11). In order to evaluate whether
lipid bodies may function as nuclear-independent alterna-
tive sites of eicosanoid production, we generated enucle-
ated eosinophils, cytoplasts, by modifying the technique of
Roos et al. (28) for cytoplast formation in neutrophils. A
typical eosinophil cytoplast preparation, devoid of nuclei
and specific granules, is shown in Fig. 6. After freshly iso-
lated eosinophils (Fig. 6 A) were layered over a discontinu-
ous gradient of Ficoll 70 containing 20 mM cytochalasin B
and subjected to centrifugation, cytoplasts (.90% pure,
Fig. 6 B) were formed by the fusion of the plasma mem-
brane around the cytoplasmic part of the cell and recovered
from the layers formed at the 12.5/16% and 16/25% Ficoll
interfaces. The nuclei and granules, also surrounded by
plasma membrane, migrated to the bottom of the gradient
(Fig. 6 C) and constituted karyoplasts.
Similar to the reaction observed with intact eosinophils,
PAF induced a dose-dependent formation of lipid bodies in
eosinophil cytoplasts (Fig. 7). WEB 2086 (10 mM, 1 h be-
fore PAF) blocked this PAF-induced lipid body formation
by 84%, indicating that PAF-induced lipid body formation
was receptor-mediated in cytoplasts as in intact eosinophils.
Moreover, PAF-induced lipid body formation in nuclei-
free cytoplast strongly correlated with increased LTC4 (Fig.
7 A) and PGE2 (Fig. 7 B) production after submaximal
stimulation with A23187 (0.5 mM). The karyoplast fraction
of eosinophils was also able to generate increased amounts
of LTC4, but not PGE2, upon stimulation (data not
shown).
Figure 4. Immunolocalization
of LTC4 synthase and COX to
lipid bodies of human eosinophils.
Human eosinophils from normal
volunteers were incubated with
PAF (1 mM, for 1 h) to induce
lipid body formation, and lipid
bodies were visualized by endoge-
nous labeling with the fluorescent
fatty acid–containing diglyceride,
1-acyl-2-(7-octyl BODIPYÔ-1-
pentanoyl)-sn-glycerol (1 mM, for
1 h). Fluorescent fatty acid–labeled
lipid bodies were visualized as
green punctate intracytoplasmic
inclusions under FITC excitation
(A, C, and E). LTC4 synthase (B)
and COX (D) were localized to
lipid bodies using anti-LTC4 and
anti-COX, respectively, affinity-
purified rabbit IgG, and glucose-
oxidase immunocytochemistry.
Rabbit IgG was used as a control
(F). Lipid bodies exhibit dark
punctate staining in B and D
which matches fluorescent lipids in
A and C, respectively. (Some fluo-
rescent lipid bodies are out of the
plane of focus and not visible.)916 Lipid Bodies: Inducible Sites for Eicosanoid Formation
The presence of 5-LO, LTC4 synthase, and COX within
eosinophil cytoplasts was analyzed by glucose oxidase im-
munocytochemical staining after stimulation of eosinophil
cytoplasts with PAF (1 mM, for 1 h) to induce lipid body
formation. Cytoplasts, stained with anti–5-LO polyclonal
antiserum (Fig. 6 D), affinity-purified rabbit anti-LTC4
synthase IgG (Fig. 6 E) or affinity-purified rabbit anti-
COX IgG (Fig. 6 F), showed the punctate cytoplasmic im-
munochemical staining indicative of lipid body localiza-
tion. The specificities of immunochemical stainings were
demonstrated by the absence of immunoreactivity when
nonimmune rabbit IgG (Fig. 5 G) or normal rabbit serum
(Fig. 5 H) were used instead of specific antibody.
Subcellular Fractionation and 5-LO Localization at Lipid
Bodies. To confirm the localization of 5-LO to lipid bod-
ies, subcellular fractions, including buoyant lipid bodies,
cytosol, microsomes, and nuclei, were isolated from dis-
rupted eosinophils. Immunoblotting with anti-5-LO rabbit
sera showed that 5-LO was dominantly in the cytosol of
eosinophils not stimulated with PAF, whereas after PAF
stimulation 5-LO was also strongly present in lipid bodies
(Fig. 8). Little 5-LO was present in the microsomal and nu-
clear fractions. In addition to the dominant 78-kD band of
5-LO, lower molecular mass bands of lesser intensity were
noted in lipid body fractions. Since such bands were also
present in the recombinant 5-LO standard, they may repre-
sent breakdown products of 5-LO. These results corrobo-
rate the immunolocalization observed in intact eosinophils,
providing evidence of the specificity of the anti–5-LO anti-
sera and demonstrating the lipid body localization of 5-LO
in PAF-stimulated eosinophils.
Discussion
In this study we report a series of complementary obser-
vations in human eosinophils which provide evidence for
novel roles of lipid bodies as specific inducible sites of para-
crine eicosanoid mediator formation. First, lipid bodies,
prominent in vivo in eosinophils and other leukocytes asso-
ciated with inflammatory reactions, can be induced to rap-
Figure 5. PAF-induced both lipid body formation and priming for
LTC4 (A) and PGE2 (B) production by human eosinophils. Eosinophils
(106/ml) were stimulated for 1 h at 378C with concentrations of PAF or
vehicle alone. Data are means 6 SEM of eicosanoids formed by eosino-
phils and lipid body numbers in eosinophils from six to eight independent
experiments. Increasing numbers of lipid bodies correlated with increased
production of each eicosanoid (r >0.97, P ,0.03 for both, Fisher’s r to z
transformation).  *Statistically significant differences (P ,0.05, paired t
test) between PAF and the vehicle. LTC4 and PGE2 in supernatants were
measured by ELISA after incubation with 0.5 mM A23187 for 15 min.
Figure 6. Eosinophil cytoplasts and immunolocalization of eicosanoid-forming enzymes. Freshly isolated eosinophils (A), eosinophil cytoplasts (B), and
karyoplasts (C) were fixed in methanol and stained with Diff-Quik (Baxter Healthcare Corp., Miami, FL). Eosinophil cytoplasts were incubated with
PAF (1 mM, for 1 h) to induce lipid body formation. 5-LO (D), LTC4 synthase (E), and COX (F) were localized at cytoplast lipid bodies using specific
anti–5-LO rabbit antiserum, affinity-purified rabbit IgG anti-LTC4 synthase, or anti-COX, respectively, and glucose-oxidase immunocytochemistry.
Substitution of the primary antibody by nonimmune rabbit serum (G) or rabbit IgG (H) were controls.917 Bozza et al.
idly form in eosinophils. Second, key eicosanoid-forming
enzymes are localized directly at eosinophil lipid bodies,
both those induced experimentally to form within 1 h and
those naturally formed in cells from HES donors. Third,
induction of lipid body formation correlates with enhanced
generation of LTC4 and PGE2. Fourth, even in anucleate
eosinophil cytoplasts, lipid bodies are inducible, correlate
with enhanced eicosanoid formation, and are discrete sites
of eicosanoid-forming enzyme localization. Together, these
results point to roles for lipid bodies as distinct, inducible
extranuclear domains involved in the generation of eico-
sanoid mediators of inflammation.
If lipid bodies are to participate in the stimulated genera-
tion of eicosanoid paracrine mediators, normal leukocytes
with few lipid bodies should be able to rapidly form in-
creased numbers of these cytoplasmic inclusions. In human
eosinophils, lipid body formation was a tightly controlled
cellular response, which developed rapidly (within 1 h) af-
ter in vitro stimulation with PAF. PAF-induced, newly
formed eosinophil lipid bodies were morphologically iden-
tical to native lipid bodies, and although PAF is a lipid,
mechanisms other than the simple incorporation of exoge-
nous lipids are involved in lipid body formation. First, the
PAF precursor and metabolite, lyso-PAF, which shares the
lipid structure of PAF but has no receptor agonist activity
(for review see reference 34), lacked the capacity to induce
lipid body formation. In addition, PAF-stimulated eosino-
phil lipid body formation was dose dependent (1028–1026
M), with significant lipid body induction at submicromolar
PAF concentrations, consistent with a receptor-dependent
process. In agreement, PAF-induced lipid body formation
was dose-dependently inhibited by the PAF receptor an-
tagonist WEB 2086. Moreover, G protein-coupled PAF
receptor signaling is pertussis toxin sensitive (35), and per-
tussis toxin significantly inhibited PAF-induced lipid body
formation. In addition to PAF receptor–initiated signaling,
additional downstream intracellular signaling pathways
were involved in eosinophil lipid body formation. A role
for PKC mediation of lipid body formation has been indi-
cated in studies using neutrophils (25, 36). In eosinophils,
the abilities of staurosporine, H-7, and two highly selective
PKC inhibitors (chelerythrine, which interacts with the
catalytic domain, and calphostin C, which acts on the regu-
latory domain of PKC) to inhibit lipid body induction are
consistent with involvement of PKC in PAF-induced lipid
body formation. Further, inhibitors of transcription (acti-
nomycin D) and translation (cycloheximide) significantly
inhibited lipid body formation induced by PAF, thus indi-
cating that the stimulated induction of lipid bodies depends
on new protein synthesis and suggesting that early response
genes are activated during the process of lipid body forma-
tion.
The definition that eosinophil lipid bodies can be rapidly
induced by PAF-initiated signaling is in accord with studies
in neutrophils which also have demonstrated that specific
signaling pathways lead to rapid lipid body induction (24,
25). However, these findings do not define how lipid bod-
ies may participate in enhanced eicosanoid synthesis. If
lipid bodies are to have roles in eicosanoid mediator forma-
tion, then the arachidonic acid present in those lipid-rich
structures must be liberated by phospholipases. Consistent
with regulated release of arachidonate occurring directly at
lipid bodies, we have recently demonstrated the cocom-
partmentalization of MAP kinases and cPLA2, the upstream
enzymes involved in arachidonic acid liberation, within
lipid bodies in U937 cells (Yu, W., P.T. Bozza, D.M. Tzi-
zik, J.P. Gray, J. Cassara, A.M. Dvorak, and P.T. Weller,
manuscript submitted for publication). Similarly, cPLA2
Figure 7. Dose-dependent effect of PAF (1028–1026M) on both lipid
body formation and priming for LTC4 (A) and PGE2 (B) production by
eosinophil cytoplasts. Cytoplasts (106/ml) were stimulated for 1 h at 378C
with PAF or vehicle alone. Data are means 6 SEM of eicosanoids formed
by cytoplasts and lipid body numbers in cytoplasts from three to four in-
dependent assays. *Significantly . value without PAF stimulation (P
,0.05). LTC4 and PGE2 in supernatants were measured by ELISA after
incubation with 0.5 mM A23187 for 15 min.
Figure 8. Immunoblotting of 5-LO in lipid bodies and other subcellu-
lar fractions of unstimulated and PAF-stimulated eosinophils. Lipid bodies
and other subcellular fractions were isolated from unstimulated and PAF-
stimulated (1 mM, 1 h) eosinophils as described in Materials and Methods.
Proteins (15 mg) from subcellular fractions were electrophoresed on 10%
SDS-PAGE gels, transferred to nitrocellulose membranes, and immuno-
blotted with anti–5-LO serum. Purified recombinant 5-LO protein was
used as a standard for the Western blot. The anti–5-LO serum recognized
a 78-kD protein, which comigrated with the purified recombinant 5-LO
standard, in subcellular fractions, prominently including the cytosol and
buoyant lipid bodies from PAF-stimulated eosinophils.918 Lipid Bodies: Inducible Sites for Eicosanoid Formation
can be demonstrated by immunocytochemistry at eosino-
phil lipid bodies (not shown).
If arachidonate is liberated intracellularly at lipid bodies,
then either arachidonate must be translocated to sites of
eicosanoid synthesis or eicosanoid formation must occur
directly at lipid bodies. Previous studies on the intracellular
localization of 5-LO have shown that 5-LO localization is
cell type specific and may vary according to the activation
state of the cell (6–10). 5-LO has been localized within the
nuclear environment (perinuclear membrane and euchro-
matin) of some cell types, including alveolar macrophages
and basophilic leukemia cells (9, 10). Using cell fraction-
ation with immunoblotting, 5-LO was found to be pre-
dominantly cytosolic in human neutrophils (9) and resting
peritoneal macrophages (37), although after activation 5-LO
could also be found in the nuclear membranes of these
cells. Stimulated leukocytes metabolize arachidonic acid via
the 5-LO pathway to form LTA4, which can degrade non-
enzymatically to form 6-trans isomers of LTB4 or can be
enzymatically converted to LTB4 or LTC4 (for review see
reference 1). Upon stimulation, human eosinophils prefer-
entially produce LTC4 as their 5-LO pathway product (31).
LTC4 synthase is the terminal LTC4-forming enzyme and
is present selectively in eosinophils, basophils, and mast
cells (31, 38, 39). In human eosinophils, the coupling of
LTA4 synthesis with LTC4 synthesis is highly efficient since
the 6-trans isomers of LTB4 do not form in ionophore-
stimulated eosinophils, as they do in neutrophils (31). Hu-
man eosinophils also generate COX-derived eicosanoids
(40), albeit in lesser quantities than LTC4. Although COX
localization is undefined in eosinophils, in other cells COX
isoforms have been localized to the endoplasmic reticulum
and the perinuclear membrane (3–5). Thus, in human
eosinophils the key eicosanoid-forming enzymes are 5-LO,
LTC4 synthase (potentially coupled in some fashion with
5-LO to form LTC4), and COX.
By means of immunocytochemistry and ultrastructural
postembedding immunogold, we have now shown that all
three key eicosanoid-forming enzymes in human eosino-
phils, 5-LO, LTC4 synthase, and COX, are localized di-
rectly at lipid bodies in eosinophils. The three enzymes are
present both in naturally formed eosinophil lipid bodies
and, of pertinence to the capacity of lipid bodies to partici-
pate in enhanced eicosanoid mediator formation, in PAF-
induced lipid bodies which are formed rapidly (within 1 h)
in intact and anucleate human eosinophils. In intact eosino-
phils, anti–5-LO staining was present in the perinuclear and
cytosolic regions, consistent with previous observations in
other cells (9, 10), and was specifically found at lipid bod-
ies, identified by their incorporation of fluorescent fatty ac-
ids (Fig. 2, A and B). Ultrastructural immunogold localiza-
tion of 5-LO in naturally formed lipid bodies in eosinophils
from an HES donor corroborated this localization and fur-
ther suggested that 5-LO was distributed within the lipid
bodies and not principally at their periphery (Fig. 3). Simi-
lar to that observed for 5-LO, LTC4 synthase was shown to
colocalize at lipid bodies (Fig. 4, C and D). Immunocy-
tochemistry of PAF-stimulated eosinophils using an anti-
COX polyclonal antibody demonstrated diffuse perinuclear
and cytoplasmic staining, consistent with previous studies
which reported perinuclear and endoplasmic reticulum lo-
calization of COX (3–5), as well as distinct punctate anti-
COX staining which precisely colocalized with fluorescent
fatty acid–labeled lipid bodies (Fig. 4, C and D). In agree-
ment, COX has been previously localized by immunogold
electron microscopy within naturally formed lipid bodies in
eosinophils and other cell types (21–23, 41). Leukocytes
can express two isoforms of COX: COX-1 (the constitu-
tive enzyme), and COX-2 (an inducible form in most
cells). Since the anti-COX antibody used in this study does
not discriminate between the two COX isoforms, further
studies are necessary to establish the isoform present in
PAF-induced lipid bodies. The compartmentalization of
three key eicosanoid-forming enzymes at lipid body do-
mains in eosinophils (Figs. 2–4, 6), even within an hour of
their induced formation, together with esterified arachido-
nate substrate (17, 20) and cPLA2, provides in one induc-
ible locale an efficient topographic means to regulate
arachidonate release and directly couple it with the requi-
site eicosanoid-forming enzymes.
Stimuli known to prime leukocytes for enhanced
eicosanoid generation, including PKC activators, arachido-
nate, and PAF (24, 25, 42–44), are also active in inducing
lipid body formation (24, 25, 36). Consistent with roles for
lipid bodies in enhanced formation and release of eicosanoids,
we demonstrated significant correlations between levels of
PAF-induced lipid body formation and amounts of en-
hanced LO- and COX-derived eicosanoids generated by
human eosinophils (Fig. 5). Analogous enhancement of
eicosanoid production by eosinophils has been observed af-
ter lipid body induction by cis-fatty acids (24). Conversely,
agents which inhibited lipid body formation also resulted in
inhibited priming for eicosanoid production. Pretreatment
of eosinophils with the protein synthesis inhibitors, actino-
mycin D or cycloheximide, inhibited not only PAF-induced
lipid body formation, but also priming for increased LTC4
and PGE2 release by eosinophils. To ascertain that PAF in-
duction of lipid body formation and priming for enhanced
eicosanoid formation was truly independent of any nuclear
pools of eicosanoid-forming enzymes or lipids, eosinophil
enucleated cytoplasts were prepared. As observed with intact
eosinophils, PAF induced dose-dependent increases in the
number of lipid bodies in eosinophil cytoplasts. Likewise,
PAF-induced lipid body formation in nuclei-free cytoplasts
strongly correlated with increased LTC4 and PGE2 produc-
tion after submaximal stimulation with A23187 (Fig. 7), and
PAF-induced eosinophil cytoplast lipid bodies were sites of
5-LO, LTC4 synthase, and COX localization (Fig. 6). Fur-
ther evidence for the localization of 5-LO at lipid bodies was
obtained by immunoblotting of isolated eosinophil subcellu-
lar fractions. After PAF stimulation of lipid body formation,
5-LO was strongly present in isolated lipid bodies (Fig. 8). In
both unstimulated and 5-LO–stimulated eosinophils, 5-LO
was abundant in the cytosol but not in the microsomal and919 Bozza et al.
nuclear fractions. Thus, lipid bodies are nuclear-independent
sites at which enhanced formation of eicosanoids may occur.
Our findings indicate that lipid bodies are inducible, cy-
toplasmic sites for eicosanoid-forming enzyme localization
and eicosanoid production. Together with recent findings
indicating that the nucleus and perinuclear membrane may
also function as important sites for eicosanoid metabolism
(5, 11), our findings of a distinct role for lipid bodies as ex-
tranuclear sites for eicosanoid formation may be indicative
of differential intracellular compartmentalization of eicosanoid
synthesis related to the autocrine or paracrine activities of
the eicosanoids. Eicosanoids formed within or around the
nucleus may function as autocrine regulators of transcrip-
tion or other processes. In contrast, lipid bodies, as rapidly
inducible structures which provide sources of arachidonate
at sites for regulated arachidonate release coupled intimately
with eicosanoid-forming enzymes, are likely to have spe-
cific roles in the generation of eicosanoids with paracrine
mediator activities. The prominence of lipid bodies in leu-
kocytes in vivo in association with a variety of inflammatory
pathological conditions (12–15, 17–19), many of which are
known to have enhanced generation of arachidonic acid
products, such as LTs and PGs, would be compatible with
this role for lipid bodies. In conclusion, our results indicate
that lipid bodies are rapidly inducible, specialized cytoplas-
mic domains for eicosanoid-forming enzyme localization
which may have specific roles in enhanced paracrine
eicosanoid mediator formation during inflammatory pro-
cesses.
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